João Chaves

João Chaves

Auto-generated profile, based on publicly available information

João Chaves

Neurology Department Centro Hospitalar Universitário de Santo António, Unidade Local de Saúde (ULS) de Santo António Porto Portugal

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 September 2013 in Brain
Verified
Journal Article
Open access
PDF file
DKDalia Kasperavičiūtė
Dalia Kasperavičiūtė
CCClaudia B. Catarino
Claudia B. Catarino
MMMar Matarin
Mar Matarin
CLCostin Leu
Costin Leu
JNJan Novy
Jan Novy
SSSanjay M. Sisodiya
Sanjay M. Sisodiya
Epilepsy comprises several syndromes, amongst the most common being mesial temporal lobe epilepsy with hippocampal sclerosis. Seizures in mesial temporal lobe epilepsy with hippocampal sclerosis are typically drug-resistant, and mesial temporal lobe epilepsy with hippocampal sclerosis is frequently associated with important co-morbidities, mandating the search for better understanding and treatment. The cause of mesial temporal lobe epilepsy with hippocampal sclerosis is unknown, but there is an association with childhood febrile seizures. Several rarer epilepsies featuring febrile seizures are caused by mutations in SCN1A, which encodes a brain-expressed sodium channel subunit targeted by many anti-epileptic drugs. We undertook a genome-wide association study in 1018 people with mesial temporal lobe epilepsy with hippocampal sclerosis and 7552 control subjects, with validation in an independent sample set comprising 959 people with mesial temporal lobe epilepsy with hippocampal sclerosis and 3591 control subjects. To dissect out variants related to a history of febrile seizures, we tested cases with mesial temporal lobe epilepsy with hippocampal sclerosis with (overall n = 757) and without (overall n = 803) a history of febrile seizures. Meta-analysis revealed a genome-wide significant association for mesial temporal lobe epilepsy with hippocampal sclerosis with febrile seizures at the sodium channel gene cluster on chromosome 2q24.3 [rs7587026, within an intron of the SCN1A gene, P = 3.36 × 10−9, odds ratio (A) = 1.42, 95% confidence interval: 1.26–1.59]. In a cohort of 172 individuals with febrile seizures, who did not develop epilepsy during prospective follow-up to age 13 years, and 6456 controls, no association was found for rs7587026 and febrile seizures. These findings suggest SCN1A involvement in a common epilepsy syndrome, give new direction to biological understanding of mesial temporal lobe epilepsy with hippocampal sclerosis with febrile seizures, and open avenues for investigation of prognostic factors and possible prevention of epilepsy in some children with febrile seizures.

15 April 2008 in Human Molecular Genetics
Verified
Journal Article
Open access
PDF file
ABAndrea Balreira
Andrea Balreira
PGPaulo Miranda Gaspar
Paulo Miranda Gaspar
DCDaniel Caiola
Daniel Caiola
JCJoão Chaves
João Chaves
IBIdalina Beirão
Idalina Beirão
MMMaria Clara Sá Miranda
Maria Clara Sá Miranda
The main clinical features of two siblings from a consanguineous marriage were progressive myoclonic epilepsy without intellectual impairment and a nephrotic syndrome with a strong accumulation of C1q in capillary loops and mesangium of kidney. The biochemical analysis of one of the patients revealed a normal β-glucocerebrosidase activity in leukocytes, but a severe enzymatic deficiency in cultured skin fibroblasts. This deficiency suggested a defect in the intracellular sorting pathway of this enzyme. The sequence analysis of the gene encoding LIMP-2 (SCARB2), the sorting receptor for β-glucocerebrosidase, confirmed this hypothesis. A homozygous nonsense mutation in codon 178 of SCARB2 was found in the patient, whereas her healthy parents were heterozygous for the mutation. Besides lacking immunodetectable LIMP-2, patient fibroblasts also had decreased amounts of β-glucocerebrosidase, which was mainly located in the endoplasmic reticulum, as assessed by its sensitivity to Endo H. This is the first report of a mutation in the SCARB2 gene associated with a human disease, which, contrary to earlier proposals, shares no features with Charcot–Marie–Tooth disease both at the clinical and neurophysiological levels.

18 November 2005 in Epilepsia
Verified
Journal Article
Closed access
PDF file
JCJ. Chaves
J. Chaves
JSJ.W. Sander
J.W. Sander

1 October 2014 in Epilepsy Research
Verified
Journal Article
Closed access
FCFernando Dias Correia
Fernando Dias Correia
JFJoel Freitas
Joel Freitas
RMRui Magalhães
Rui Magalhães
JLJoão Lopes
João Lopes
JRJoão Ramalheira
João Ramalheira
JCJoão Chaves
João Chaves

1 November 2011 in Seizure: European Journal of Epilepsy
Verified
Journal Article
Closed access
JCJoão Chaves
João Chaves
IBIdalina Beirão
Idalina Beirão
ABAndrea Balreira
Andrea Balreira
PGPaulo Miranda Gaspar
Paulo Miranda Gaspar
DCDaniel Caiola
Daniel Caiola
JLJosé L. Lima
José L. Lima

11 September 2018 in Genes
Verified
Journal Article
Open access
PDF file
Liliana MatosLiliana Matos
Liliana Matos
Ana Joana DuarteAna Joana Duarte
Ana Joana Duarte
DRDiogo Ribeiro
Diogo Ribeiro
JCJoão Chaves
João Chaves
Olga AmaralOlga Amaral
Olga Amaral
Sandra AlvesSandra Alves
Sandra Alves
Unverricht-Lundborg disease (ULD) is a common form of progressive myoclonic epilepsy caused by mutations in the cystatin B gene (CSTB) that encodes an inhibitor of several lysosomal cathepsins. Presently, only pharmacological treatment and psychosocial support are available for ULD patients. To overcome the pathogenic effect of the ULD splicing mutation c.66G>A (exon 1), we investigated whether an antisense oligonucleotide therapeutic strategy could correct the defect in patient cells. A specific locked nucleic acid (LNA) antisense oligonucleotide was designed to block a cryptic 5′ss in intron 1. Overall, this approach allowed the restoration of the normal splicing pattern. Furthermore, the recovery was both sequence and dose-specific. In general, this work provides a proof of principle on the correction of a CSTB gene defect causing ULD through a mutation-specific antisense therapy. It adds evidence to the feasibility of this approach, joining the many studies that are paving the way for translating antisense technology into the clinical practice. The insights detailed herein make mutation-based therapy a clear candidate for personalized treatment of ULD patients, encouraging similar investigations into other genetic diseases.